Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30097143 | 0.91 | PDE5A (0.40) | PDE5AHTTPTGS2 | |
| SCHEMBL27409202 | 0.91 | PDE5A (0.40) | PDE5AHTTPTGS2 | |
| SCHEMBL27409189 | 0.82 | PDE5A (0.47) | PDE5ABCDIN3DPTGS2TP53 | |
| SCHEMBL27409146 | 0.81 | PDE2A (0.38) | HTTBCDIN3DTP53PDE2ABRD4 | |
| SCHEMBL27409147 | 0.78 | PDE2A (0.36) | HTTBCDIN3DTP53PDE2A | |
| SCHEMBL27409973 | 0.78 | PDE4A (0.41) | HTTBCDIN3DBRD4BRD9 | |
| SCHEMBL27409190 | 0.77 | KMT2A (0.50) | PDE5AHTT | |
| SCHEMBL27409964 | 0.77 | LPL (0.40) | BCDIN3DTP53PDE2A | |
| SCHEMBL27409196 | 0.76 | PDE5A (0.46) | PDE5APTGS2TP53 | |
| SCHEMBL27409193 | 0.75 | MEN1 (0.52) | PDE5APTGS2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209005-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209005-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2022197734-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209005-A1 | BICYCLIC HETEROARYL BORONATE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, ENTPD5 | PDE5A 22/4885HTT 3703/4885BCDIN3D 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.